


Anti-Mumps Virus

**Sensitive IgG and IgM
antibody determination**



sebia 

The new language of life



Infections with Mumps Virus

More than a childhood disease

Pathogen

The enveloped ss(-)RNA mumps virus is a member of the *paramyxoviridae* family. Mumps (*parotitis epidemica*) is the result of a primary infection with the mumps virus and belongs to the classic childhood diseases. Infections primarily affect the salivary glands, but can also result in deafness and infertility.

Epidemiology


Mumps viruses are widespread worldwide. Local epidemics occur in regular intervals. The incidence has increased in recent years.

Transmission

The mumps virus is transmitted through direct contact or through droplet infections.

Clinical Symptoms

Mumps often occurs with fever and uni- or bilateral inflammation of the parotid gland (parotitis, 80 %). The pancreas can also be affected (pancreatitis, 2 – 5 %). In immunocompetent individuals, the disease is usually harmless and provides a lifelong immunity. The most common complications are meningitis (5 – 15 %) and encephalitis. The disease rarely leads to uni- or bilateral deafness (1 / 10,000). In addition, mumps orchitis in boys and men can lead to infertility.



Diagnosis

The diagnosis of infections with mumps virus is based on the clinical symptoms and confirmed by laboratory analyses. IgM und IgG antibodies are generated during primary infection. Whereas IgM antibodies are usually no longer detectable a few weeks after primary infection, IgG antibodies usually remain life-long and are correlated with immune protection.


Anti-Mumps Virus IgG / IgM Abs. *Sensitive antibody determination*

Antigen

The Alegria Anti-Mumps Virus IgG und IgM Abs. Monotests are based on a preparation of inactivated mumps viruses (strain Enders) for a sensitive determination of IgG and IgM antibodies.

Calibration

The Alegria Anti-Mumps IgG and IgM Abs. Monotests are calibrated using internal reference samples. Results are expressed in U/mL.



Sensitivity and Specificity

	Sensitivity	Specificity	Diagnostic Efficiency
Anti-Mumps Virus IgG	> 99 %	97.7%	> 99 %
Anti-Mumps Virus IgM	87.5 %	> 99 %	> 99 %

Precision Anti-Mumps Virus IgG

	Intraassay Repeatability		Interassay Reproducibility	
	Antibody Activity (U/mL)	Coefficient of Variation (CV)	Antibody Activity (U/mL)	Coefficient of Variation (CV)
Sample 1	8.2 U/mL	1.9 %	7.4 U/mL	3.9 %
Sample 2	28.5 U/mL	2.8 %	26.4 U/mL	1.5 %
Sample 3	138.7 U/mL	6.1 %	121.0 U/mL	3.3 %

Precision Anti-Mumps Virus IgM Abs.

	Intraassay Repeatability		Interassay Reproducibility	
	Antibody Activity (U/mL)	Coefficient of Variation (CV)	Antibody Activity (U/mL)	Coefficient of Variation (CV)
Sample 1	12.0 U/mL	5.3 %	12.0 U/mL	5.8 %
Sample 2	24.0 U/mL	6.5 %	23.4 U/mL	7.0 %
Sample 3	28.7 U/mL	3.9 %	33.9 U/mL	13.9 %





Product Highlights

- ELISA-based random access determination of IgG and IgM antibodies against mumps virus
- Full automation and complete traceability with Alegria 2
- Lab-on-a-Strip: ready-to-use test-specific reagents in individually sealed and barcoded Alegria Monotest strips
- Sensitive detection of IgG and IgM antibodies by use of inactivated mumps viruses (strain Enders)
- Integrated Rf-absorption prior to IgM detection
- Excellent diagnostic efficiency
- High reproducibility for reliable test results
- Economical all-in-one Alegria Monotests, particularly suited for small series
- Flexible combination of Alegria Monotests for optimal workflow efficiency

Ordering *information*

- Anti-Mumps Virus IgG**ORG 908G**
- Anti-Mumps Virus IgM Abs.**ORG 908MX**



Scan here **for more information**
about Alegria Anti-Mumps Virus
Monotests

Literature

Lam, E. *et al.* (2020) Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity. *Clin. Microbiol. Rev.* 33, e00151-19.

Su, S. B. *et al.* (2020) Current Status of Mumps Virus Infection: Epidemiology, Pathogenesis, and Vaccine. *Int. J. Environ. Res. Public Health* 17, 1686.

Ravault, S. *et al.* (2019) Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates. *J. Infect. Dis.* 220, 1462 – 8.



ORGENTEC Diagnostika GmbH |

Carl-Zeiss-Straße 49-51 | 55129 Mainz | Deutschland |

Tel. : +49 6131 / 9258-0 | Fax : +49 6131 / 9258-58 | E-mail:

orgentec@orgentec.com | www.orgentec.com

©Sebia2026 ■ **ORGENTEC Diagnostika GmbH** - Carl-Zeiss-Straße 49-51 | 55129 Mainz | Deutschland - Ref.: QM211352 - AMUVLIEN - 02/2025 - 02 - Non-contractual illustration - ORGENTEC reserves the right to modify at any time and without notice the information contained in this document intended for healthcare professionals. This document contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Carefully read the instructions in the reagent package inserts and instrument manuals.